Business
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
-- Data Show Improvement and Stabilization in Renal Function -- Unprecedented median proteinuria reduction of 64.4 percent seen in the narsoplimab Phase 2
About this update from Omeros Corporation
[{"type":"text","content":"\n-- Data Show Improvement and Stabilization in Renal Function --\n\n\nUnprecedented median proteinuria reduction of 64.4 percent seen in the narsoplimab Phase 2 clinical trial predicts a 41.6-year delay in need for dialysis compared to standard of care\n\n\nNarsoplimab is the first candidate targeting IgA nephropathy to demonstrate long-term improvement or sustained stabilization in eGFR\n\n\n58 percent of patients received only one narsoplimab treatment course (12 weekly doses) or less annually, with 25 percent of patients showing improvement in eGFR despite having significant, longstanding IgA nephropathy with high-risk comorbidities\n\n\nNarsoplimab-treated patients showed response irrespective of stage of their advanced disease state\n\n\nNarsoplimab was well tolerated with no treatment-related serious adverse events\n\n\nLong-term data from the narsoplimab Phase 2 clinical trial were presented yesterday at the Annual Meeting of the American Society of Nephrology by Richard Lafayette, M.D., Stanford University Professor of Medicine-Nephrology and Director of the Stanford Glomerular Disease Center\n\n\n \n\n SEATTLE--(BUSINESS WIRE)--\nOmeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with narsoplimab in this trial was associated with an unprecedented median reduction in proteinuria of 64.4 percent. Now, long-term follow-up (out to 35 months) of these patients shows a markedly slowed rate of decline of estimated glomerular filtration rate (eGFR). Using the same analytical approach adopted by other companies* to determine the impact of proteinuria reduction on long-term risk of need for dialysis, a 64.4 percent reduction in proteinuria is predicted to delay progression to renal dialysis by 41.6 years compared to standard of care. While other companies have reported up to 1-year follow-up data on eGFR, this is the first time that sustained stabilization, let alone improvement, of eGFR through long-term follow-up has been reported for any novel therapeutic in development for IgA nephropathy. ARTEMIS-IGAN, the Phase 3 clinical trial of narsoplimab in IgA nephropathy, is ongoing.\n\n“The long-term data are highly supportive of a key role for lectin pathway inhibition in the future ...